The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study.
D. B. Agus
Consultant or Advisory Role - Takeda
W. M. Stadler
Consultant or Advisory Role - Takeda
D. H. Shevrin
No relevant relationships to disclose
L. Hart
Research Funding - Millennium
G. R. MacVicar
No relevant relationships to disclose
O. Hamid
Consultant or Advisory Role - Millennium
Research Funding - Millennium
J. D. Hainsworth
No relevant relationships to disclose
M. E. Gross
No relevant relationships to disclose
J. Wang
Employment or Leadership Position - Millennium
L. de Leon
Employment or Leadership Position - Millennium
Stock Ownership - Millennium
D. MacLean
Employment or Leadership Position - Millennium
R. Dreicer
Consultant or Advisory Role - Millennium
Honoraria - Millennium